13F Holdings
中文EN

DTIL PRECISION BIOSCIENCES INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1357874 · Fiscal year ends 05/21

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY6,353.0%
TTM net income YoY53.9%
TTM EPS YoY103.6%
Revenue 3-yr CAGR-4.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-80.3%
Net margin-85.6%
FCF margin-115.0%
EBITDA margin-77.8%

Returns

ROE-112.7%
ROA-36.0%
ROIC (approx.)—
Asset turnover0.42x

Leverage & solvency

Liabilities / assets57.0%
Debt / equity0.00x
Current ratio10.47x
Interest coverage-28.56x

Cash quality & payout

Operating cash flow / net income1.34x
Accruals ratio12.4%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$34.26M$68.70M$48.73M$25.10M$115.53M
R&D expense$54.17M$59.56M$53.38M$46.12M$115.24M
SG&A expense$32.24M$35.30M$39.09M$41.28M$39.67M
Operating income-$52.15M-$26.16M-$43.74M-$62.31M-$39.38M
Interest expense$1.42M$1.78M$2.23M$1.11M$132,000
Pretax income-$45.72M$7.17M———
Income tax$0$0———
Net income-$45.72M$7.17M-$61.32M-$111.64M-$30.60M
EBITDA-$50.68M-$22.76M-$36.92M-$54.51M-$30.39M
EPS (basic)-3.561.05-15.96-38.10-0.52
EPS (diluted)-3.561.04-15.96-38.10-0.52
Weighted avg. shares (diluted)12.83M6.88M3.84M2.93M58.69M
Balance sheet
Cash & equivalents$110.82M$108.47M$116.68M$189.58M$143.66M
Short-term investments$4.76M$413,000———
Receivables$0$229,000$901,000$720,000$488,000
Current assets$118.74M$94.99M$136.36M$199.10M$161.75M
PP&E, net$1.43M$3.09M$6.34M$11.81M$25.15M
Intangibles$1.17M$622,000$400,000$731,000$2.05M
Total assets$154.42M$136.39M$159.78M$238.17M$211.50M
Current liabilities$8.91M$14.98M$49.99M$59.66M$35.98M
Long-term debt———$22.22M$2.48M
Total debt———$22.22M$2.48M
Total liabilities$62.17M$80.00M$140.92M$177.74M$120.33M
Shareholders' equity$92.25M$56.39M$18.86M$60.43M$91.17M
Net debt———-$167.35M-$141.19M
Shares outstanding24.09M8.20M4.16M3.70M60.90M
Cash flow statement
Operating cash flow-$65.84M-$58.45M-$84.11M-$45.75M-$10.85M
Capital expenditure$85,000$250,000$1.96M$3.32M$5.05M
Free cash flow-$65.93M-$58.70M-$86.07M-$49.07M-$15.91M
Investing cash flow-$634,000-$215,000$5.83M-$3.32M-$5.80M
Financing cash flow$95.16M$50.45M$5.39M$94.98M$70.52M
Depreciation & amortization$1.47M$3.40M$6.82M$7.80M$8.98M
Stock-based compensation$10.19M$12.60M$14.04M$19.20M$16.51M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.